Basilea is planning to wrap up a big year with a $190 million IPO on Nasdaq. The Swiss biotech filed the IPO on Friday--the same day the EU provided formal approval for its antifungal drug isavuconazole, now sold as Cresemba in the U.S. by its partner Astellas.